Thalidomide, the notorious drug which caused horrendous birth defects in the 1950s and 1960s, is close to making a comeback as an anticancer drug. Drug firm Celgene of Warren, New Jersey, has applied to European drug authorities for permission to sell thalidomide to treat multiple myeloma, a fatal cancer of the bone marrow. In clinical trials the drug performed well against the disease. It will take Europe seven months or more to reach a verdict on the drug, which will not be prescribed to pregnant women or those considering having children.
More from New Scientist
Explore the latest news, articles and features
Technology
Test moderators use AI-generated writing to judge literacy standards
News
Mind
THC in cannabis may reduce nightmares in people with PTSD
News
Environment
Fishers detonate a bomb every hour on one Indonesian coral reef
News
Environment
How bad is the UK drought and how long will it continue?
News
Popular articles
Trending New Scientist articles